ライフサイエンスコーパス: mitogen-activated protein kinase kinase

1 phorylation and activation of KSR-bound MEK (mitogen-activated protein kinase kinase).

2 locked by inhibitors of protein kinase C and mitogen-activated protein kinase kinase.

3 inhibitors of either farnesyl transferase or mitogen-activated protein kinase kinase.

4 n is a metalloprotease that cleaves upstream mitogen-activated protein kinase kinases.

5 ted and ddPCR confirmed somatic mutations in mitogen activated protein kinase kinase 1 (MAP2K1), the

6 lleles in Ras-like without CAAX 1 (RIT1) and mitogen-activated protein kinase kinase 1 (MAP2K1) and p

7 n has been linked to its ability to activate mitogen-activated protein kinase kinase 1 (MEK) and mito

8 Conversely, conditional mitogen-activated protein kinase kinase 1 (Mek1) activat

9 Overexpression of V1, V2, or GIT1 activated mitogen-activated protein kinase kinase 1 (MEK1) and ext

10 gulated kinase (ERK)1/2 and Akt and both the mitogen-activated protein kinase kinase 1 (MEK1) and pho

11 The response was blocked by a specific mitogen-activated protein kinase kinase 1 (MEK1) inhibit

12 AK-null cells, constitutively activated (CA) mitogen-activated protein kinase kinase 1 (MEK1) restore

13 s article, we demonstrate that LPA activates mitogen-activated protein kinase kinase 1 (MEKK1) in a G

14 Ectopic expression of constitutively active mitogen-activated protein kinase kinase 1 (MKK1) resulte

15 rrolo[3,4-c]carbazole-12-p ropanenitrile and mitogen-activated protein kinase kinase 1 2-(2-amino-3-m

16 ion of BRCA1-induced ERK1/2 activation using mitogen-activated protein kinase kinase 1 and 2 (MEK1/2)

17 The expression of constitutively activated mitogen-activated protein kinase kinase 1 enhanced caspa

18 Chemical inhibition of PI-3K and mitogen-activated protein kinase kinase 1 inhibited E(2)

19 y, and the effects of LT were independent of mitogen-activated protein kinase kinase 1 inhibition.

20 ression of the alpha7 integrin or use of the mitogen-activated protein kinase kinase 1 inhibitor U012

21 FR with AG1478 or small interfering RNA), or mitogen-activated protein kinase kinase 1 or 2 (MKK1/2 w

22 activating mutation in exon 2 of MEK1 (i.e., mitogen-activated protein kinase kinase 1 or MAP2K1) tha

23 of Ras or a dominant-negative form of MEK1 (mitogen-activated protein kinase kinase 1).

24 othecin by expression of constitutive active mitogen-activated protein kinase kinase 1, an upstream k

25 that the hepatocyte growth factor activator, mitogen-activated protein kinase kinase 1, and phosphati

26 sed by pharmacologic and siRNA inhibitors of mitogen-activated protein kinase kinase 1/2 (MEK1/2) and

27 phynylthio)butadiene]-specific inhibitors of mitogen-activated protein kinase kinase 1/2 (MEK1/2) blo

28 ERK1/2), and the combination of SMI-4a and a mitogen-activated protein kinase kinase 1/2 (MEK1/2) inh

29 gonism of PGE2 release was achieved with the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inh

30 between 7-hydroxystaurosporine (UCN-01) and mitogen-activated protein kinase kinase 1/2 (MEK1/2) inh

31 tion that 20S reduction has little effect on mitogen-activated protein kinase kinase 1/2 (MEK1/2) sig

32 , cardiac expression of phospho-Akt, phospho-mitogen-activated protein kinase kinase 1/2 and phospho-

33 Preclinical evaluation of the mitogen-activated protein kinase kinase 1/2 inhibitor se

34 anner, combined exposure to OSU-03012 with a mitogen-activated protein kinase kinase 1/2 inhibitor, p

35 Both Ly294002 and U0126, a mitogen-activated protein kinase kinase 1/2 inhibitor, r

36 ess signaling pathways demonstrated that the mitogen-activated protein kinase kinase 1/2 pathway acti

37 by cytokines and suppressed by inhibition of mitogen-activated protein kinase kinase 1/2, whereas STE

38 The RAF-mitogen-activated protein kinase kinase 1/2-extracellula

39 nd degradation, and subsequent activation of mitogen-activated protein kinase kinase 1/2.

40 al-regulated kinases 1/2 phosphorylation was mitogen-activated protein kinase kinases 1/2 dependent b

41 Use of mitogen-activated protein kinase kinases 1/2 inhibitors

42 nhibitor of the dual-specificity kinases MEK(mitogen-activated protein kinase kinase) -1 and MEK2 , i

43 We further find that modulation of Mitogen Activated Protein Kinase Kinase-1/2 (MAP2K1/2, M

44 Here, we demonstrate that acetylation of the mitogen-activated protein kinase kinase-1 (MEK1) stimula

45 NF-kappaB-inducing kinase (NIK) and mitogen-activated protein kinase kinase-1 (MEKK-1) were

46 Mitogen-activated protein kinase kinase 2 (MEK2) is a ki

47 idated six candidate proteins, including the mitogen-activated protein kinase kinase 2 (MEK2), that i

48 Mitogen-activated protein kinase kinase 3 (MKK3) is a du

49 activation could be blocked by RNAi against mitogen-activated protein kinase kinase 3 and 6 (MKK3/6)

50 Even though 34F(2) has LeTx, there was no mitogen-activated protein kinase kinase 3 cleavage and p

51 orylation of p38 and its upstream regulators mitogen-activated protein kinase kinase 3/6 and apoptosi

52 stressed by osmotic shock (OSM) activate the mitogen-activated protein kinase kinase(3/6)-p38 signali

53 (MAP) kinase cascade consisting of GhMAP3K15-Mitogen-activated Protein Kinase Kinase 4 (GhMKK4)-Mitog

54 un NH(2)-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4 (JNKK1/MKK4) a

55 ses HAESA (HAE) and HAESA-like 2 (HSL2), the Mitogen-Activated Protein Kinase Kinase 4 (MKK4) and MKK

56 ine-inducible, constitutively active, mutant mitogen-activated protein kinase kinase 4 (MKK4) into th

57 The mitogen-activated protein kinase kinase 4 (MKK4) is acti

58 l death in vitro and in vivo by inactivating mitogen-activated protein kinase kinase 4 (MKK4), JNK, a

59 ar accumulation from SEPW1 depletion require mitogen-activated protein kinase kinase 4 (MKK4).

60 ic expression of JNK and its upstream kinase mitogen-activated protein kinase kinase 4 led to DNA dam

61 R256C mutation revealed attenuation of MKK4 (mitogen-activated protein kinase kinase 4) activation th

62 kinase/extracellular signal-related kinase 1/mitogen-activated protein kinase kinase 4), c-Jun N-term

63 MAP2K4 encodes a dual-specificity kinase (mitogen-activated protein kinase kinase 4, or MKK4) that

64 rough development in floral receptacles in a MITOGEN-ACTIVATED PROTEIN KINASE KINASE 4/5-dependent ma

65 m signaling showed a prominent activation of mitogen-activated protein kinase kinase 4/6 and c-Jun NH

66 /2, p38 stress-activated protein kinase, and mitogen-activated protein kinase kinases 4/7 shows littl

67 Mitogen-activated protein kinase kinase-4 (MKK4/SEK1) co

68 Our results showed that mitogen-activated protein kinase kinase 5 (MEK5) was mar

69 n kinase kinase/MEK/MAPKK 1-4 and 6, but not mitogen-activated protein kinase kinase 5 and 7.

70 Mitogen-activated protein kinase kinase 5, a downstream

71 cific transgenic overexpression of activated mitogen-activated protein kinase kinase 6, a direct indu

72 mice with fibroblast-specific activation of mitogen-activated protein kinase kinase 6-p38 developed

73 proapoptotic protein JNK1 by upregulation of mitogen-activated protein kinase kinase 7 (MKK7) and dow

74 as associated with increases in the upstream mitogen-activated protein kinase kinase 7 (MKK7) and the

75 A specific upstream activator of JNKs is the mitogen-activated protein kinase kinase 7 (MKK7).

76 ivates downstream effectors that include the mitogen-activated protein kinase kinase 7 (MKK7)/c-Jun-N

77 lightly stimulated the JNK-activating kinase mitogen-activated protein kinase kinase 7, the latter wa

78 Inhibition of mitogen-activated protein kinase kinase abolishes the NO

79 n of K(ATP) is indirect and requires Ras and mitogen-activated protein kinase kinase activities.

80 Focusing on mitogen-activated protein kinase kinase and Bcl-XL targe

81 chain phosphorylation by PAK is mediated by mitogen-activated protein kinase kinase and extracellula

82 n was partially blocked by inhibition of the mitogen-activated protein kinase kinase and protein kina

83 Whereas host targets of LF (mitogen-activated protein-kinase kinases) and EF (cAMP-d

84 in kinase B and a pathway involving DSOR1, a mitogen-activated protein kinase kinase, and an extracel

85 hatidyl inositol 3-kinase, protein kinase C, mitogen-activated protein kinase kinase, and p38-mitogen

86 ypoxic A431 cells, whereas inhibition of the mitogen-activated protein kinase kinase by PD98059 reduc

87 In contrast to the rapid cleavage of mitogen-activated protein kinase kinases by LeTx, the de

88 translocation to the cytosol (as assessed by mitogen-activated protein kinase kinase cleavage), K(+)

89 Induction of mitogen-activated protein kinase kinase-dependent signal

90 n kinase kinase kinase, or in MKK4/MAP2K4, a mitogen-activated protein kinase kinase directly downstr

91 K4/MAP2K4, mice lacking MKK7/MAP2K7, another mitogen-activated protein kinase kinase directly downstr

92 through Akt/protein kinase B (Akt/PKB), the mitogen-activated protein kinase kinase DSOR1, and extra

93 In metazoans, the Ras-Raf-MEK (mitogen-activated protein-kinase kinase)-ERK (extracellu

94 because blocking this pathway, but not MEK (mitogen-activated protein kinase kinase)/ERK (extracellu

95 (phosphatidylinositol 3-kinase)/Akt and MEK (mitogen-activated protein kinase kinase)/Erk pathways pr

96 e blocked both by pertussis toxin and by the mitogen-activated protein kinase kinase/ERK inhibitor [1

97 h the PPARgamma receptor but may involve the mitogen-activated protein kinase kinase/ERK pathway and

98 tion of the epidermal growth factor receptor-mitogen-activated protein kinase kinase-extracellular si

99 We find that VEGFD-mitogen-activated protein kinase kinase-extracellular si

100 Mitogen-activated protein kinase kinase/extracellular re

101 After finding that the rat sarcoma/mitogen-activated protein kinase kinase/extracellular re

102 expression in a manner dependent on Mek/Erk (mitogen-activated protein kinase kinase/extracellular si

103 s induced by concomitant interruption of the mitogen-activated protein kinase kinase/extracellular si

104 mulated translation and signaled through the mitogen-activated protein kinase kinase/extracellular si

105 duction involving protein kinase A, src, and mitogen-activated protein kinase kinase/extracellular si

106 rst examples of T3SS effectors implicated in mitogen-activated protein kinase kinase/extracellular si

107 ation of transforming growth factor beta and Mitogen-activated protein kinase kinase/extracellular si

108 ating event [i.e., the activation of the Raf/mitogen-activated protein kinase kinase/extracellular si

109 /calmodulin-dependent kinase II) or MEK/ERK (mitogen-activated protein kinase kinase/extracellular si

110 n target of rapamycin (mTOR) pathway and the mitogen-activated protein kinase kinase/extracellular si

111 de content of human adipocytes by activating mitogen-activated protein kinase kinase/extracellular si

112 p-regulation of IL-8 in DU145 depends on the mitogen-activated protein kinase kinase/extracellular si

113 caused a robust and sustained activation of mitogen-activated protein kinase kinase/extracellular si

114 15-mediated growth advantage is abolished by mitogen-activated protein kinase kinase/extracellular si

115 Surprisingly, activation of the mitogen-activated protein kinase kinase/extracellular si

116 effect was decreased by a M3R antagonist, a mitogen-activated protein kinase kinase/extracellular si

117 n of p53 at Ser-15 and the initiation of the mitogen-activated protein kinase kinase/extracellular-re

118 The serine-threonine mitogen-activated protein kinase kinase family member T-

119 as an intracellular endopeptidase targeting mitogen-activated protein kinase kinases, growing eviden

120 d-type ARAF, this mutant was a highly active mitogen-activated protein kinase kinase in vitro and was

121 ein kinase kinase, indicating that potential mitogen-activated protein kinase kinase-independent Raf

122 rmacological inhibition of the Raf substrate mitogen-activated protein kinase kinase, indicating that

123 lockade of this rebound activation with MEK (mitogen-activated protein kinase kinase) inhibition enha

124 ensis-infected mice with the highly-specific mitogen activated protein kinase kinase inhibitor, CI-10

125 The mitogen-activated protein kinase kinase inhibitor 2-(2-a

126 Addition of a mitogen-activated protein kinase kinase inhibitor to rap

127 The ErbB inhibitor PD158780 and the mitogen-activated protein kinase kinase inhibitor U0126

128 ration were inhibited after treatment with a mitogen-activated protein kinase kinase inhibitor, U0126

129 olished with omega-conotoxin, cilnidipine or mitogen-activated protein kinase kinase inhibitor.

130 re given intrathalamic infusions of the MEK (mitogen-activated protein kinase-kinase) inhibitor 1,4-d

131 inhibited, respectively, by U0126, PD98059 (mitogen-activated protein kinase kinase inhibitors), SP6

132 -dependent protein kinase signaling, and two mitogen-activated protein kinase kinase inhibitors, U012

133 e cholangiocytes that was blocked by PKA and mitogen-activated protein kinase kinase inhibitors.

134 ASK1, also known as MAP3K5), a member of the mitogen-activated protein kinase kinase kinase (MAP3K) f

135 Members of the mitogen-activated protein kinase kinase kinase (MAP3K) f

136 Mixed-lineage kinase-3 (MLK3) is a mammalian mitogen-activated protein kinase kinase kinase (MAP3K) t

137 Tumor progression locus 2 (Tpl2), a mitogen-activated protein kinase kinase kinase (MAP3K) t

138 MAPK/ERK kinase kinase 3 (MEKK3) is a mitogen-activated protein kinase kinase kinase (MAP3K) t

139 This PCD requires mitogen-activated protein kinase kinase kinase (MAPKKK a

140 nd repressing the downstream gene encoding a mitogen-activated protein kinase kinase kinase (MAPKKK)

141 Mixed lineage kinase 7 (MLK7) is a mitogen-activated protein kinase kinase kinase (MAPKKK)

142 tosis signal-regulating kinase 1 (ASK1) is a Mitogen-Activated Protein Kinase Kinase Kinase (MAPKKK,

143 IS8 gene revealed that it encodes a putative mitogen-activated protein kinase kinase kinase (MAPKKK;

144 effect of expressing a heterologous tobacco mitogen-activated protein kinase kinase kinase (Nicotian

145 The mitogen-activated protein kinase kinase kinase 1 (MAP3K1

146 Here we show that mitogen-activated protein kinase kinase kinase 1 (MAP3K1

147 by current methods, we discovered recurrent mitogen-activated protein kinase kinase kinase 1 (Map3k1

148 action is not fully understood, a functional mitogen-activated protein kinase kinase kinase 1 (MAP3K1

149 Here, we show that the mitogen-activated protein kinase kinase kinase 1 (MEKK1)

150 ylation of c-Jun caused by overexpression of mitogen-activated protein kinase kinase kinase 1 (Mekk1)

151 ondrial ribosomal protein S30 gene (MRPS30), mitogen-activated protein kinase kinase kinase 1 gene (M

152 appaB pathway, including the upstream kinase mitogen-activated protein kinase kinase kinase 14 (MAP3K

153 We investigated the role of the mitogen-activated protein kinase kinase kinase 14/NF-kap

154 usly known and unknown to be associated with mitogen-activated protein kinase kinase kinase 2 (MEKK2)

155 401.3, c.1323C>G; NP_002392, p.Iso441Met) in mitogen-activated protein kinase kinase kinase 3 (MAP3K3

156 ich protein kinase C substrate (MARCKS), and mitogen-activated protein kinase kinase kinase 3 (MAP3K3

157 lar kinase expression library, we identified mitogen-activated protein kinase kinase kinase 8 (MAP3K8

158 The oncogene mitogen-activated protein kinase kinase kinase 8 (MAP3K8

159 er Osaka thyroid (COT) kinase, also known as mitogen-activated protein kinase kinase kinase 8 (MAP3K8

160 to stimulate cell proliferation involves the mitogen-activated protein kinase kinase kinase B-Raf, we

161 Mixed-lineage kinase 1 (MLK1) is a mitogen-activated protein kinase kinase kinase capable o

162 nesis by down-regulating the ortholog of the mitogen-activated protein kinase kinase kinase dual leuc

163 ancer osaka thyroid (COT) is a member of the mitogen-activated protein kinase kinase kinase family of

164 that Wallenda (Wnd), a protein kinase of the mitogen-activated protein kinase kinase kinase family, b

165 a activated kinase-1 (TAK1), a member of the mitogen-activated protein kinase kinase kinase family, h

166 eta-activated kinase (TAK1), a member of the mitogen-activated protein kinase kinase kinase family.

167 mixed lineage kinases (MLKs), members of the mitogen-activated protein kinase kinase kinase family.

168 The Arabidopsis mitogen-activated protein kinase kinase kinase gene, YOD

169 n activation by inhibiting the expression of mitogen-activated protein kinase kinase kinase kinase 1

170 RPs for inflammation genes revealed that the mitogen-activated protein kinase kinase kinase kinase 4

171 e suggested a role for endothelial cell (EC) mitogen-activated protein kinase kinase kinase kinase 4

172 Previous studies revealed a paradox whereby mitogen-activated protein kinase kinase kinase kinase 4

173 Here we demonstrate that the Sterile-20-like mitogen-activated protein kinase kinase kinase kinase 4

174 By quantitative proteomics, we identified mitogen-activated protein kinase kinase kinase kinase 4

175 Mitogen-activated protein kinase kinase kinase kinase 4

176 nine nucleotide exchange factor Asef and the mitogen-activated protein kinase kinase kinase kinase ge

177 , our studies focused on the redox-sensitive mitogen-activated protein kinase kinase kinase known as

178 g a point mutation that renders inactive the mitogen-activated protein kinase kinase kinase MEKK4 exh

179 Mixed lineage kinase 3 (MLK3) is a mitogen-activated protein kinase kinase kinase member th

180 (Arabidopsis thaliana) gene MEKK1 encodes a mitogen-activated protein kinase kinase kinase that has

181 hase of APAP-induced JNK activation, but the mitogen-activated protein kinase kinase kinase that medi

182 ibers, including, most prominently, MEKK4, a mitogen-activated protein kinase kinase kinase that was

183 Mixed lineage kinase 3 (MLK3) functions as a mitogen-activated protein kinase kinase kinase to activa

184 Receptor-like proteins and a mitogen-activated protein kinase kinase kinase were prev

185 eviously, we reported that both MAPKKKalpha (mitogen-activated protein kinase kinase kinase) and the

186 (2+) or cAMP on regrowth require the MAPKKK (mitogen-activated protein kinase kinase kinase) DLK-1.

187 Apoptosis signaling kinase 1 (ASK1), a mitogen-activated protein kinase kinase kinase, is invol

188 tion was dependent on activation of RhoA and mitogen-activated protein kinase kinase kinase, MEKK1, l

189 also known as dual leucine zipper kinase), a mitogen-activated protein kinase kinase kinase, or in MK

190 optosis signal-regulating kinase 1 (ASK1), a mitogen-activated protein kinase kinase kinase, plays a

191 stimulates the association of Dab2 with the mitogen-activated protein kinase kinase kinase, TAK1.

192 Recent studies have shown that mutations in mitogen-activated protein kinase kinase kinase-4 (Mekk4)

193 These included MAP3K5 (mitogen-activated protein kinase kinase kinase-5), which

194 Mitogen-activated protein kinase kinase kinase-Ste11 (MA

195 In addition, 4 mitogen-activated protein kinase kinase kinases, 1 mitog

196 finger homeodomain transcription factors and mitogen-activated protein kinase kinase kinases, respect

197 t be a new histone H3 kinase at the level of mitogen-activated protein kinase kinase kinases.

198 stic phenotype that was sensitive to RAF and mitogen-activated protein kinase kinase (MAP2K1) inhibit

199 Two mitogen-activated protein kinase kinase (MAPK2, also kno

200 's pro-survival effects were associated with mitogen activated protein kinase kinase (MAPKK)-->p42/p4

201 , proteolytically inactivates members of the mitogen-activated protein kinase kinase (MAPKK or MEK) f

202 se known targets include five members of the mitogen-activated protein kinase kinase (MAPKK) family o

203 een demonstrated to cleave and to inactivate mitogen-activated protein kinase kinases (MAPKKs) that p

204 st Saccharomyces cerevisae has four distinct mitogen-activated protein kinase kinases (MAPKKs), each

205 first trimester decidua via a Gq-Ca(2+)-cSrc-mitogen-activated protein kinase kinase-mediated pathway

206 n protein kinase C, calcium mobilization and mitogen-activated protein kinase kinase (MEK 1/2).

207 nositol 3-kinase (PI 3-kinase) (wortmannin), mitogen-activated protein kinase kinase (MEK) (PD98059),

208 e protein kinase Calpha/betaI isozyme (PKC), mitogen-activated protein kinase kinase (MEK) 1 and 2, a

209 Enforced expression of constitutively active mitogen-activated protein kinase kinase (MEK) 1 or myris

210 microg/mL) inhibited the kinase activity of mitogen-activated protein kinase kinase (MEK) 1/2 and re

211 Hit characterization revealed that mitogen-activated protein kinase kinase (MEK) 1/2 inhibi

212 , we show that pharmacological inhibition of mitogen-activated protein kinase kinase (MEK) activates

213 t inhibition of PKD blocks mitotic Raf-1 and mitogen-activated protein kinase kinase (MEK) activation

214 racellular glutathione levels, which inhibit mitogen-activated protein kinase kinase (MEK) activity t

215 The cascade comprising Raf, mitogen-activated protein kinase kinase (MEK) and extrac

216 The kinase pathway comprising RAS, RAF, mitogen-activated protein kinase kinase (MEK) and extrac

217 of phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase kinase (MEK) but are kn

218 KSR1 mutant bound constitutively to RAF and mitogen-activated protein kinase kinase (MEK) but could

219 utadiene (U0126) of an HGF downstream kinase mitogen-activated protein kinase kinase (MEK) induced th

220 To compare efficacy of the mitogen-activated protein kinase kinase (MEK) inhibitor

221 h paradoxical MAPK activation; addition of a mitogen-activated protein kinase kinase (MEK) inhibitor

222 lated kinase (ERK) pathway as treatment with mitogen-activated protein kinase kinase (MEK) inhibitor

223 Mitogen-activated protein kinase kinase (MEK) inhibitor

224 Treatment of cells with the mitogen-activated protein kinase kinase (MEK) inhibitor

225 anced cutaneous melanoma were treated with a mitogen-activated protein kinase kinase (MEK) inhibitor

226 fibroblast growth factor receptor (FGFR) or mitogen-activated protein kinase kinase (MEK) inhibitor

227 of rapamycin (mTOR) inhibitors, but not the mitogen-activated protein kinase kinase (MEK) inhibitor,

228 typically considered an exquisitely specific mitogen-activated protein kinase kinase (MEK) inhibitor,

229 e received intraperitoneal injections of the Mitogen-activated protein kinase kinase (MEK) inhibitor,

230 spatial learning, which can be reversed by a mitogen-activated protein kinase kinase (MEK) inhibitor.

231 tant BRAF(V600E) tumours but, in contrast to mitogen-activated protein kinase kinase (MEK) inhibitors

232 rous retinal disturbances in patients taking mitogen-activated protein kinase kinase (MEK) inhibitors

233 ary Nras(G12D) AMLs with 2 potent allosteric mitogen-activated protein kinase kinase (MEK) inhibitors

234 o novel series of highly potent biaryl amine mitogen-activated protein kinase kinase (MEK) inhibitors

235 The mitogen-activated protein kinase kinase (MEK) kinase 1 (

236 is known to be mediated by the canonical Raf-mitogen-activated protein kinase kinase (MEK) kinase cas

237 Mitogen-activated protein kinase kinase (MEK) mutations

238 ing the cells with an inhibitor (PD98059) of mitogen-activated protein kinase kinase (MEK) or by tran

239 showing that inhibitors of BRAF-V600E and/or mitogen-activated protein kinase kinase (MEK) reach thei

240 Extracellular signal-regulated/mitogen-activated protein kinase kinase (MEK) signaling

241 Finally, inhibition of mitogen-activated protein kinase kinase (MEK) synergized

242 any additional treatment, the inhibition of mitogen-activated protein kinase kinase (MEK) with U0126

243 inositide-3 kinase (PI3 kinase), Akt, Raf-1, mitogen-activated protein kinase kinase (MEK), and extra

244 ctivity and basal and stimulated Ras, Raf-1, mitogen-activated protein kinase kinase (MEK), and MAPK

245 geting the shared ERK1/2 upstream activator, mitogen-activated protein kinase kinase (MEK), and trans

246 TSLP induced mitogen-activated protein kinase kinase (MEK), c-Fos, in

247 eptors produced either enhanced or sustained mitogen-activated protein kinase kinase (MEK), Casitas B

248 nges in calcium, and phosphorylation of Akt, mitogen-activated protein kinase kinase (MEK), extracell

249 Ras-mediated signaling pathway involving the mitogen-activated protein kinase kinase (MEK), known to

250 paB, extracellular signal-regulated kinase > mitogen-activated protein kinase kinase (MEK), p38, and

251 I HDACs requires activity of the ERK kinase, mitogen-activated protein kinase kinase (MEK), revealing

252 small-molecule screen found an inhibitor of mitogen-activated protein kinase kinase (MEK), which act

253 Intact mitogen-activated protein kinase kinase (Mek)-extracellu

254 pathways known to couple to translation, the mitogen-activated protein kinase kinase (MEK)-extracellu

255 therapeutic importance of the activated BRAF-mitogen-activated protein kinase kinase (MEK)-extracellu

256 ed kinase 2 (ERK2) with its upstream kinase, mitogen-activated protein kinase kinase (MEK).

257 mation by suppressing the kinase activity of mitogen-activated protein kinase kinase (MEK).

258 kinase activity and for its interaction with mitogen-activated protein kinase kinase (MEK).

259 2i) of glycogen synthase kinase 3 (Gsk3) and mitogen-activated protein kinase kinase (MEK).

260 We identified that the mitogen-activated protein kinase kinase (MEK)/extracellu

261 a poor prognosis, but targeting the RAS/RAF/mitogen-activated protein kinase kinase (MEK)/extracellu

262 The RAF/mitogen-activated protein kinase kinase (MEK)/extracellu

263 overexpressing RARalpha2 activated STAT3 and mitogen-activated protein kinase kinase (MEK)/extracellu

264 Because mitogen-activated protein kinase kinase (MEK)/extracellu

265 intrinsic chemoresistance by activating the mitogen-activated protein kinase kinase (MEK)/extracellu

266 emurafenib, which selectively inhibits B-RAF/mitogen-activated protein kinase kinase (MEK)/extracellu

267 k2(fl/fl-Cre)) and mice expressing activated mitogen-activated protein kinase kinase (Mek)1 in the he

268 usly, we showed that Cdk5 phosphorylation of mitogen-activated protein kinase kinase (MEK)1 inhibits

269 Recent work indicates that mitogen-activated protein kinase kinase (MEK)1 signaling

270 f mitogen-activated protein kinase activator mitogen-activated protein kinase kinase (MEK)1, and the

271 th factor receptor (ERBB1) via a Galpha(i)-, mitogen-activated protein kinase kinase (MEK)1/2-, and m

272 tivation of the PI3Kshort right arrowAKT and mitogen-activated protein kinase kinase (MEK)short right

273 rine neutrophils, leading to the cleavage of mitogen-activated protein kinase kinase/MEK/MAPKK 1-4 an

274 hosphorylation of B-cell linker protein, the mitogen-activated protein kinase kinase MEK1/2, and ERK,

275 98059 and UO126, selective inhibitors of the mitogen-activated protein kinase kinase MEK1/2, in a dos

276 Here we show that PI3K-C2beta regulates mitogen-activated protein kinase kinase (MEK1/2) and ext

277 niquely used for differential binding of two mitogen-activated protein kinase kinases, MEK5 and MKK7,

278 use of its proteolytic activities toward the mitogen-activated protein kinase kinases (MEKs).

279 metalloprotease that cleaves and inactivates mitogen-activated protein kinase kinases (MEKs).

280 growth factor-beta-activated kinase 1 (TAK1)-mitogen-activated protein kinase kinase (MKK) 3/6-p38alp

281 ludes proteasome inactivation, activation of mitogen-activated protein kinase kinase (MKK)3/MKK6, act

282 metalloprotease that cleaved and inactivated mitogen-activated protein kinase kinases (MKK).

283 ed as a kinase by signaling from Rac1 to the mitogen-activated protein kinase kinase MKK3.

284 new integrin ligation and requires both the mitogen-activated protein kinase kinase MKK4 and p21-act

285 ghly specific protease, exclusively cleaving mitogen-activated protein kinase kinases (MKKs) and rode

286 Although the mitogen-activated protein kinase kinases (MKKs) are the

287 atic loss of phosphorylation of MKK3 and -6, mitogen-activated protein kinase kinases (MKKs) regulate

288 some inhibitor lactacystin, by inhibitors of mitogen-activated protein kinase kinase or protein kinas

289 We also show that inhibition of mitogen-activated protein kinase kinase or Raf kinase ca

290 n M1 CM that induces CXCL12 expression via a mitogen-activated protein kinase kinase-p38-signal trans

291 Langerhans cells stained for phospho-mitogen-activated protein kinase kinase (phospho-MEK) an

292 data revealed that the expression of several mitogen-activated protein kinase kinase-regulatory genes

293 particular, we report synergistic effects of mitogen-activated protein kinase kinase, ribosomal S6 ki

294 pqn-41 expression is controlled by the mitogen-activated protein kinase kinase SEK-1, which fun

295 Wnt signals, a temporal control pathway, and mitogen-activated protein kinase kinase signaling contro

296 f bone marrow-derived dendritic cells with a mitogen activated protein kinase kinase-specific inhibit

297 a synthetic peptide substrate and endogenous mitogen-activated protein kinase kinase substrates and k

298 itor 2'-amino-3'-methoxyflavone (PD98059) of mitogen-activated protein kinase kinase, the upstream ki

299 In this study, we determined that mitogen-activated protein kinase kinase transforming gro

300 s encoding ENHANCED DISEASE SUSCEPTIBILITY1, mitogen-activated protein kinase kinase, WRKY, PATHOGENE